Volume 21, Number 10—October 2015
Research
Epidemiology of Lyme Disease, Nova Scotia, Canada, 2002–2013
Table 2
Characteristics of 329 reported LD case-patients, Nova Scotia Canada, 2002–2013*
Characteristic | No. (%) |
---|---|
Sex | |
M | 200 (60.8) |
F |
129 (39.2) |
Age group, y | |
0–9 | 31 (9.4) |
10–19 | 33 (10.0) |
20–29 | 17 (5.2) |
30–39 | 17 (5.2) |
40–49 | 32 (9.7) |
50–59 | 67 (20.4) |
60–69 | 76 (23.1) |
70–79 | 44 (13.4) |
>80 |
12 (3.6) |
Case definition met | |
Confirmed | 241 (73.3) |
Probable | |
EM with history of exposure to endemic region | 66 (20.1) |
Clinical evidence of illness without exposure
to endemic region with laboratory evidence |
22 (6.7) |
Symptom† | |
Rash, any reported | 295 (89.7) |
Influenza-like illness | 229 (69.6) |
EM, physician-diagnosed | 175 (53.2) |
Recurrent brief episodes of large joint swelling | 77 (23.4) |
Bell palsy | 23 (7.0) |
Nervous system symptoms, excluding Bell palsy | 21 (6.4) |
Cardiovascular system signs |
4 (1.2) |
History of tick bite | |
Definite | 87 (26.4) |
Possible, exposure to wooded or brushy regions | 199 (60.5) |
Unknown |
43 (13.1) |
DHA of residence‡ | |
DHA 1 | 235 (71.4) |
DHA 2 | 21 (6.4) |
DHA 3 | 9 (2.7) |
DHA 4 | 4 (1.2) |
DHA 5 | 1 (0.3) |
DHA 6 | 8 (2.4) |
DHA 7 | 4 (1.2) |
DHA 8 | 2 (0.6) |
DHA 9 |
45 (13.7) |
Hospitalized | 13 (4.0) |
*Endemic regions as defined in June 2014. Some cases classified to exposure retrospectively (i.e., case occurred before endemic region were declared). DHA, District Health Authority; EM, erythema migrans; LD, Lyme disease.
†More than 1 symptom might be reported per case-patient. Rash, any reported, includes EM. Cardiovascular system signs include atrioventricular block, mycarditis, other.
‡DHA 1, endemic regions declared in 2003 and 2012; DHA 2, endemic regions declared in 2008 and 2011; DHA 6, endemic region declared in 2010; DHA 9, endemic region declared in 2006.
Page created: September 22, 2015
Page updated: September 22, 2015
Page reviewed: September 22, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.